This randomized, double-blind, placebo-controlled trial evaluated the effects of intravenous glutathione in 30 patients with alcoholic liver disease (ALD). Patients treated with glutathione showed statistically significant improvements in liver enzyme levels—specifically reductions in GGT, AST, and ALT—indicating reduced liver inflammation and oxidative stress. The therapy was well-tolerated, with no significant
